Selvita S.A.   Report issue

For profit Phase 2
Founded: Krakow Poland (2007)

Organization Overview

First Clinical Trial
2017
NCT03008187
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ryvu Therapeutics SA | Selvita S.A.

Active Ingredients

Drugs in Phase 2 Trials (2)

sel120 (2 trials)

sel24 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Preleukemia (Phase 1)

Syndrome (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2